Cryptosporidium Infection and Human Colorectal Cancer

Launched by LILLE CATHOLIC UNIVERSITY · Mar 31, 2020

Keywords

ClinConnect Summary

This clinical trial is investigating whether a tiny parasite called Cryptosporidium, which can cause digestive infections, might be linked to colorectal cancer in humans. Previous animal studies suggested a possible connection between this parasite and digestive cancers, but researchers want to explore this further in people. The goal of the study is to find out how common Cryptosporidium infections are among patients with colorectal cancer and to identify the specific types of this parasite present in these patients.

To participate in the trial, participants must be at least 18 years old. For those with colorectal cancer, they need to have a diagnosis before starting chemotherapy or radiation and be scheduled for surgery. There are also control participants who can join if they have benign (non-cancerous) conditions or other types of digestive cancers. All participants will need to provide informed consent, meaning they understand the study and agree to take part. Throughout the trial, participants will undergo testing to determine if they have had a Cryptosporidium infection. This research could help clarify the relationship between this parasite and cancer, potentially guiding future treatment and prevention strategies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Cases:
• • Age ≥ 18 years old
• • Patients with colonic adenocarcinoma/intraepithelial neoplasia diagnosed prior to chemotherapy or radiotherapy who will undergo scheduled surgery. Patients with rectal cancer with indication for neoadjuvant treatment will still be included, but only biopsies used for diagnosis will be used
• • Patient capable of receiving informed information
• • Written informed consent
• • Affiliation to a social security scheme
• Controls:
• • Age ≥ 18 years old
• • Patients with endoscopic indication for benign pathology
• • Patients with indication for colectomy for benign pathology
• • Patients with digestive cancer (stomach, oesophagus, biliary, pancreatic, etc.) of any type other than colorectal cancer before chemotherapy or radiotherapy
• • Patient capable of receiving informed information
• • Written informed consent
• • Affiliation to a social security scheme
• Exclusion Criteria:
• • Patients undergoing pre-operative chemotherapy.
• • Patients who have already had chemotherapy for less than one year or other immunosuppressive treatment